世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
リンパ腫治療薬市場。世界の業界動向、シェア、サイズ、成長、機会、そして2021-2026年の予測Lymphoma Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global lymphoma treatment market grew at a CAGR of around 8% during 2015-2020. Lymphoma refers to a type of cancer characterized by the rapid development of abnormal malignant cells in the lymp... もっと見る
サマリーThe global lymphoma treatment market grew at a CAGR of around 8% during 2015-2020. Lymphoma refers to a type of cancer characterized by the rapid development of abnormal malignant cells in the lymphatic system. It usually targets the white blood cells (WBCs), or lymphocytes, in lymph nodes, spleen, thymus and bone marrow and impairs the immune response of the body. As a result, the patient develops swelling in the lymph nodes, high fever, weight loss, dyspnea and fatigue. Some of the commonly used lymphoma therapeutics include radiation, chemo and monoclonal antibody therapy, active surveillance, bone marrow transplant and immunotherapy drugs. These therapeutics are widely used for the treatment of both Hodgkin and non-Hodgkin lymphoma.The increasing prevalence of non-Hodgkin lymphoma across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness among the masses regarding the available diagnostic technologies and treatment alternatives for lymphoma is also creating a positive outlook for the market. Hospitals and other diagnostic centers are using innovative tests and imaging technologies, such as computed tomography (CT), Magnetic Resonance Imaging (MRI) and positron emission tomography (PET) scans, for accurate identification of the cancer cells and timely treatment. Additionally, various technological advancements, including the development of innovative immune checkpoint inhibitors, which block proteins from binding together and increase the response strength of T-cells against cancer cells, are contributing to the market growth. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further. Looking forward, IMARC Group expects the global lymphoma treatment market to continue its moderate growth during the next five years. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global lymphoma treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type, test type and drug. Breakup by Type: Hodgkin Lymphoma Non-Hodgkin Lymphoma Breakup by Test Type: Chemotherapy Radiation Therapy Immunotherapy Targeted Therapy Biologic Therapy Others Breakup by Drug: Adcetris Rituxan Opdivo Imbruvica Keytruda Revlimid Others Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Spectrum Pharmaceuticals, Takeda Pharmaceutical Company Ltd. and Teva Pharmaceutical Industries Ltd. Key Questions Answered in This Report: How has the global lymphoma treatment market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global lymphoma treatment market? What are the key regional markets? What is the breakup of the market based on the type? What is the breakup of the market based on the test type? What is the breakup of the market based on the drug? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global lymphoma treatment market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Lymphoma Treatment Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Type 6.1 Hodgkin Lymphoma 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Non-Hodgkin Lymphoma 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Test Type 7.1 Chemotherapy 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Radiation Therapy 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Immunotherapy 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Targeted Therapy 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Biologic Therapy 7.5.1 Market Trends 7.5.2 Market Forecast 7.6 Others 7.6.1 Market Trends 7.6.2 Market Forecast 8 Market Breakup by Drug 8.1 Adcetris 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Rituxan 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Opdivo 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Imbruvica 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Keytruda 8.5.1 Market Trends 8.5.2 Market Forecast 8.6 Revlimid 8.6.1 Market Trends 8.6.2 Market Forecast 8.7 Others 8.7.1 Market Trends 8.7.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia-Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Abbott Laboratories 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis 14.3.2 Bristol-Myers Squibb Company 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 Financials 14.3.2.4 SWOT Analysis 14.3.3 Eli Lilly and Company 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis 14.3.4 F. Hoffmann-La Roche Ltd. 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.4.3 SWOT Analysis 14.3.5 Johnson & Johnson 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.5.4 SWOT Analysis 14.3.6 Merck & Co. Inc. 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 Financials 14.3.6.4 SWOT Analysis 14.3.7 Novartis AG 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.7.3 Financials 14.3.7.4 SWOT Analysis 14.3.8 Spectrum Pharmaceuticals 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.8.3 Financials 14.3.8.4 SWOT Analysis 14.3.9 Takeda Pharmaceutical Company Ltd. 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.9.4 SWOT Analysis 14.3.10 Teva Pharmaceutical Industries Ltd. 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 Financials 14.3.10.4 SWOT Analysis
SummaryThe global lymphoma treatment market grew at a CAGR of around 8% during 2015-2020. Lymphoma refers to a type of cancer characterized by the rapid development of abnormal malignant cells in the lymphatic system. It usually targets the white blood cells (WBCs), or lymphocytes, in lymph nodes, spleen, thymus and bone marrow and impairs the immune response of the body. As a result, the patient develops swelling in the lymph nodes, high fever, weight loss, dyspnea and fatigue. Some of the commonly used lymphoma therapeutics include radiation, chemo and monoclonal antibody therapy, active surveillance, bone marrow transplant and immunotherapy drugs. These therapeutics are widely used for the treatment of both Hodgkin and non-Hodgkin lymphoma.The increasing prevalence of non-Hodgkin lymphoma across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness among the masses regarding the available diagnostic technologies and treatment alternatives for lymphoma is also creating a positive outlook for the market. Hospitals and other diagnostic centers are using innovative tests and imaging technologies, such as computed tomography (CT), Magnetic Resonance Imaging (MRI) and positron emission tomography (PET) scans, for accurate identification of the cancer cells and timely treatment. Additionally, various technological advancements, including the development of innovative immune checkpoint inhibitors, which block proteins from binding together and increase the response strength of T-cells against cancer cells, are contributing to the market growth. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further. Looking forward, IMARC Group expects the global lymphoma treatment market to continue its moderate growth during the next five years. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global lymphoma treatment market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type, test type and drug. Breakup by Type: Hodgkin Lymphoma Non-Hodgkin Lymphoma Breakup by Test Type: Chemotherapy Radiation Therapy Immunotherapy Targeted Therapy Biologic Therapy Others Breakup by Drug: Adcetris Rituxan Opdivo Imbruvica Keytruda Revlimid Others Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Spectrum Pharmaceuticals, Takeda Pharmaceutical Company Ltd. and Teva Pharmaceutical Industries Ltd. Key Questions Answered in This Report: How has the global lymphoma treatment market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global lymphoma treatment market? What are the key regional markets? What is the breakup of the market based on the type? What is the breakup of the market based on the test type? What is the breakup of the market based on the drug? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global lymphoma treatment market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Lymphoma Treatment Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Type 6.1 Hodgkin Lymphoma 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Non-Hodgkin Lymphoma 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Test Type 7.1 Chemotherapy 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Radiation Therapy 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Immunotherapy 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Targeted Therapy 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Biologic Therapy 7.5.1 Market Trends 7.5.2 Market Forecast 7.6 Others 7.6.1 Market Trends 7.6.2 Market Forecast 8 Market Breakup by Drug 8.1 Adcetris 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Rituxan 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Opdivo 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Imbruvica 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Keytruda 8.5.1 Market Trends 8.5.2 Market Forecast 8.6 Revlimid 8.6.1 Market Trends 8.6.2 Market Forecast 8.7 Others 8.7.1 Market Trends 8.7.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia-Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Abbott Laboratories 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis 14.3.2 Bristol-Myers Squibb Company 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 Financials 14.3.2.4 SWOT Analysis 14.3.3 Eli Lilly and Company 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis 14.3.4 F. Hoffmann-La Roche Ltd. 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.4.3 SWOT Analysis 14.3.5 Johnson & Johnson 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.5.4 SWOT Analysis 14.3.6 Merck & Co. Inc. 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 Financials 14.3.6.4 SWOT Analysis 14.3.7 Novartis AG 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.7.3 Financials 14.3.7.4 SWOT Analysis 14.3.8 Spectrum Pharmaceuticals 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.8.3 Financials 14.3.8.4 SWOT Analysis 14.3.9 Takeda Pharmaceutical Company Ltd. 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.9.4 SWOT Analysis 14.3.10 Teva Pharmaceutical Industries Ltd. 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 Financials 14.3.10.4 SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（その他）の最新刊レポート
IMARC Services Private Limited. 社の最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/10/15 10:26 150.67 円 164.75 円 199.57 円 |
